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Background: Fatty acid-binding protein 2 (FABP2) is an intracellular protein expressed exclusively in the enterocytes
of proximal small intestine. FABP2 has a high affinity for saturated and unsaturated long-chain fatty acids and is
believed to be involved in the absorption and transport of dietary fatty acids.
Methods: This is a case–control study conceded in 438 T2DM cases and 460 subjects with normal glucose levels
and non-obese considered as healthy controls. Allelic discrimination was performed using TaqMan single-
nucleotide polymorphism was carried out by real time-polymerase chain reaction (RT-PCR) assays using purified
DNA.
Results: Clinical data and anthropometric measurements except age, glucose levels and lipid profile of the patients
were significantly different from those of the controls (p < 0.05). Statistical analyses failed to show any type of
significant association of the polymorphism between cases and controls. However logistic regression analyses
was suggests that the TT genotype is significantly associated with male patients (p = 0.001). None of the allele or
genotypes of FABP2 A54T was associated with T2DM cases versus the controls (AT genotype, OR = 0.85
(0.64-1.12), p = 0.25; TT genotype, OR = 0.66 (0.39-1.11), p = 0.11; T allele, 0.82 (0.67-1.02), p = 0.08).
Conclusion: In conclusion, this study suggests that the above named variant in FABP2 gene is not potential
contributor to the risk of T2DM and related traits in a Saudi population. However TT genotype is a risk factor for the
disease in males.
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Type 2 diabetes mellitus (T2DM) is a chronic degenerative
disease, phenotypically and genetically characterized by in-
sulin resistance (IR) in insulin-target tissues, and impaired
insulin secretion from pancreatic β-cells [1]. T2DM affects
nearly 31.6% individuals in the Kingdom of Saudi Arabia
[2]. The interaction of genetic and environmental factors
is universally acknowledged as the primary underlying
T2DM mechanism. The T2DM risk in the first degree* Correspondence: imkhan@ksu.edu.sa
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unless otherwise stated.relatives of T2DM patients is 3.62 times that in the com-
mon population, so the researchers of various countries
make great efforts to explore the T2DM susceptible
genes. Once the T2DM susceptible genes are sought
out, it means that the T2DM prevention clues have been
found. It is an effective measure to screen the T2DM
susceptible population and prevent T2DM progress. It
is now generally considered that T2DM is not a sole
disorder, but a multigenic disorder with extensive her-
edity heterogeneous, categorized by high levels of glu-
cose and metabolic disorders [3,4]. Obesity is one of the
complication for T2DM and the leading cause of pre-
ventable deaths and a serious health complications in
the Saudi Arabia [5].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Age (Years) 45.99 ± 7.77 53.5 ± 10.78 <0.0001
Weight (kg) 76.61 ± 14.52 77.37 ± 13.55 0.41
Height (cm) 161.25 ± 8.79 161.10 ± 9.30 0.80
Body mass index (kg/m2) 29.22 ± 5.58 29.9 ± 5.89 0.95
Sex: Male/Female (52.6%)/(47.4%) (56.8%)/(43.2%) 0.0002
SBP (mmHg) 114.80 ± 8.04 125.83 ± 9.96 <0.0001
DBP (mmHg) 75.81 ± 6.20 81.25 ± 4.82 0.0001
Waist (cms) 89.75 ± 14.19 95.3 ± 18.96 <0.0001
Hips (cms) 101.75 ± 14.72 99.64 ± 16.52 0.61
FBS (mmol/L) 5.23 ± 0.61 12.92 ± 4.60 <0.0001
Triglycerides (mmol/L) 1.62 ± 0.86 2.24 ± 1.62 <0.0001
Cholesterol (mmol/L ) 5.04 ± 0.96 5.61 ± 1.26 <0.0001
HDL-C (mmol/L ) 0.64 ± 0.23 0.84 ± 0.37 <0.0001
LDL-C (mmol/L) 3.66 ± 0.85 3.76 ± 1.05 0.0008
Glucose (mmol/L) 5.7 ± 1.2 9.4 ± 1.5 0.0002
Insulin (μU/mL) 12.5 ± 1.8 16.2 ± 2.2 0.0002
HOMA-IR 3.15 ± 1.9 6.8 ± 2.4 0.00008
Note: Data represented as mean ± SD for continuous variables, pValues for
independent t-test are given. A p-value significant at <0.05. NA, Not Analyzed/
Not Applicable.
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ful tools to identify genetic variants that are associated
with common diseases. So far, GWAS identified at least
50–52 genetic loci robustly associated with T2DM [6].
Several genetic markers have now been implicated for
T2DM development pathways involved in the disease
[7,8]. Fatty acid binding protein 2 (FABP2) has been stud-
ied as one of the marker, due to its role in the uptake,
intracellular metabolism and excretion of long chain fatty
acids. This gene is located on 4q28-q31 chromosomal re-
gion, consist of approximately 3.4 kbs. Many polymor-
phisms in FABP2 gene have already linked with metabolic
phenotypes. The most extensively studies polymorphism
was Alanine54threnonine (A54T) substitution at codon 54
of exon 2 that results from G to A nucleotide substitution
and affects primary protein structure [9,10]. This change
affects the ability of the protein to transport dietary fatty
acids, which may elevate saturated fatty acids level in the
serum which might induce endothelial dysfunction leading
to increased cardiovascular mortality [11].
The aim of the present study was to investigate the
contribution of A54T genetic polymorphism identified by
Baier et al [12] in the FABP2 variants to risk of T2DM in a
Saudi population, since this polymorphism results in a
functionally altered FABP2 protein which confers suscepti-
bility to metabolic disorders like T2DM, thereby to con-
tribute to the personalized prevention of this condition
and A54T polymorphism has been associated with T2DM
disease in many but not all studies.
Materials and methods
Selection of subjects
This is a case–control study carried out in King Saud
University, Riyadh, Saudi Arabia. In this study we have
collected in about 900 subjects; 438 T2DM cases and
460 healthy controls from the capital city. All the normal
controls were selected from the general population
based on normal glucose values and non-obese subjects.
The details of the collection of patients, inclusion and
exclusion criteria were described in the prior publication
[1]. Ethical approval for the study was achieved from the
ethics committee, King Saud University. Written informed
consent was obtained from each patient. Anthropometric
and biochemical measurements of the patients involved in
this study has been described in the prior publication [1].
DNA extraction and genotyping
5 mL of the venous blood was collected into plain (coagu-
lated) and EDTA (anticoaggulated) tubes. Plain vacutainer
consist of 3 mL of the serum sample was used to analyze
the biochemical parameters and 2 mL of the EDTA sam-
ple was used for molecular analysis. Genomic DNA was
extracted from peripheral blood leukocytes using Norgen
DNA extraction kit (Norgen Biotek corp, Canada). DNAsamples were stored at −80°C. The rs1799883 polymorph-
ism was genotyped using a TaqMan® SNP genotyping
assay (Assay ID: C_2834835_10) on a 7300HT sequence
detection system (Applied Biosystems, USA). Primers and
probes were obtained from Applied Biosystems as Assays-
by-Design™. Cases and controls were ensured to have even
treatment during the assay procedure, and each plate
included negative controls (with no DNA). Plates were
read on the ABI Prism 7300 using the Sequence Detection
Software (Applied Biosystems) using 40 PCR cycles (92°C
denaturation for 15 seconds, 60°C annealing/extension
for 60 seconds). Measurements were repeated for samples
with failed genotypes. Assays that did not show >95%
concordance were discarded and replaced with alterna-
tive assays with the same tagging properties.
Statistical analysis
All statistical analysis was carried out using the statistical
program i.e. statistical package for social sciences (IBM
SPSS 19.0 SPSS Inc., Chicago, USA). The difference of
mean age of patients and controls were significantly differ-
ent (Table 1). Hence in order to overcome the significance
difference of mean age, logistic regression was performed
and it was found that patients with ages 35 (1 patient), 72
(2 patients), 77 (2 patients), 84 (2 patients), 85 (2 patients)
and 86 (2 patients) years were redundant whereas rest all
the patient ages were significantly not different from those
Table 2 Distribution of FABP2 A54T genotypes and alleles of this study
Genotype Patients’ n (%) Controls n (%) OR (CI = 95%) P value χ2
1 d. f.
AA 220 (51.52) 260 (56.52) 1 (reference) 1 (reference)
AT 170 (39.81) 171 (37.17) 0.85 (0.64-1.12) 0.25 1.12
TT 37 (8.66) 29 (6.30) 0.66 ( 0.39-1.11) 0.11 2.43
A 610 (71.42) 691 (75.10) 1 (reference) 1 (reference)
T 224 (28.57) 229 (24.89) 0.82 (0.67-1.02) 0.08 3.06
AA + AT vs TT 0.7 (0.42-1.17) 0.18 1.79
TT + AT vs AA 1.22 (0.93-1.59) 0.13 2.22
The genotypic and allelic frequencies and dominant as recessive models of patients are significantly not different from controls.
Table 3 Genotypic distribution according to sex
Patients
AA AT TT
Male 122 95 31
Female 98 86 6
Total 220 181 37
Controls
Male 136 95 13
Female 124 76 16
Total 260 171 29
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the further calculations if genotypic and allelic analyses.
The sex ratio of patients and controls were also differ-
ent significantly. So, separate multiple analyses after
logistic regressions were performed for patient and con-
trols. The allele and genotype frequencies of FABP2
gene in patients were compared to controls by chi-square
analysis. The distribution of the genotypes deviates from
Hardy-Weinberg equilibrium (HWE). Clinical characteris-
tics of all the subjects were expressed as mean ± SD. Con-
tinuous variables were compared between the groups
using two-tailed student t-test. Odds ratios (ORs) and 95%
CI, with adjustment for age, sex and BMI were calculated
using multiple logistic regression analysis. All tests were
conducted at the p < 0.05 level of significance.
Results
Clinical characteristics
In this case–control study, we have carried out in almost
900 subjects; 438 patients with T2DM (216 females and
244 males, 45.99±7.77 years old) and 460 normal control
subjects (200 female and 238 male, 53.5 ± 10.78 years
old). The mean age was 60 years for patients and 59 years
for the control group. Clinical and anthropometric data
are revealed in Table 1 for T2DM patients and control
subjects. The results show that T2DM subjects were
significantly older than controls but anthropometric
measurements and hip were not significant (p > 0.05).
T2DM subjects appear to have higher levels of SBP,
DBP, fasting glucose, insulin, HOMA-IR and lipid profile
and waist (p < 0.05).
Genotype frequencies
Results for the genotypic distribution of FABP2 A54T
polymorphism and the frequency of A and T alleles in
patients and controls have been tabulated in Table 2. The
genotype distribution for A54T polymorphism showed no
deviation from HWE in both the case and control groups
(χ2 = 0.37, p = 0.54). Genotyping of the A54T polymorph-
ism in the FABP2 gene revealed that the allelic frequency
of T allele was 0.285 in cases and 0.248 in controls (OR-0.82 (95% CI = 0.67-1.02); p = 0.08). There were no signifi-
cant differences in both the genotypic and allelic frequen-
cies between the cases as well as controls. However upon
multiple logistic regression analysis TT genotype was
found to be associated with male patients (OR = 1.24 95%
CI = 0.09-0.60, p = 0.001) (Tables 3 and 4). FABP2 geno-
typic frequencies of A54A, A54T, and T54T were 56.5%,
37.2%, and 6.3% in the control group, 51.52%, 39.81% and
8.66% in the T2DM group; allelic frequencies of Ala and
Thr were 0.75 and 0.25 for the control group, 0.71 and
0.29 for the T2DM group. The odds ratio for any genotype
of A54T SNP was not significantly related with the risk
of developing T2DM in this studied population (for
AA + AT vs TT; OR-0.7 (95% CI = 0.42-1.17); p = 0.12
and for TT + AT vs AA; OR-1.22 (95% CI = 0.93-1.59);
p = 0.25) from the Saudi population.
Discussion
FABP2 is an intracellular protein expressed in the villus
tips of the small intestine, has a high affinity for saturated
and unsaturated long-chain fatty acids and is believed to
be involved in the absorption and transport of dietary fatty
acids [13]. The association between fatty acid metabolism
and IR is well known, and the FABP2 gene has been sug-
gested as a possible candidate gene in the development of
IR and T2DM [14]. A54T polymorphism in FABP2 was
investigated as a possible genetic factor associated with
T2DM and Obesity. Studies examining the association of
Table 4 Calculation for the association of A54T genotypes
with T2DM patients and control in male and female sexes





Female 1.1 (0.74-1.65) 0.62
TT
Male 1 (reference)





Female 0.87 (0.59-1.29) 0.5
TT
Male
Female 1.35 (0.62-2.91) 0.44
OR, Odds ratio, 95% CI-95% confidence interval; multiple logistic regression
calculated by SPSS v.19, AA genotype was set as zero because redundancy
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contradictory and inconclusive [10]. The product of T al-
lele of FABP2 possesses a greater affinity for long-chain
FA than the A allele [15]. In addition, individuals with the
T allele of this polymorphism were more insulin resistant
than were those with the A allele [12]. The T allele was
also shown to be associated with higher plasma levels of
LDL-C [16] and dyslipidemia (high plasma concentration
of triglycerides and low concentration of HDL-C) [17]. In
addition, the T allele of A54T polymorphism has previ-
ously been associated with atherothrombotic cerebral in-
farction in individuals with metabolic syndrome [18] and a
parental history of stroke in the Swedish population [19].
Moreover, it was associated with a 2- to 3.5- fold increase
in cardiovascular risk in dyslipidemic men with diabetesTable 5 Association Studies of FABP2 A54T gene polymorphi
S. No Population Cases Controls
1 Germany - 68
2 Japan 228 813
3 Japan 636 1106
4 Japan 313 971
5 Brazil 72 37
6 Mexico - 131
7 Brazil 513 529
8 Brazil 26 529
9 Spain 108 101
10 Present Study 438 460compared with their dyslipidemic nondiabetic counter-
parts [20]. We have now shown that A54T polymorphism
was not significantly associated with T2DM, with the minor
allele representing the risk factor for this condition.
In the present study we investigated the association
of FABP2 A54T polymorphism with T2DM in a Saudi
population. To the best of our knowledge, this is the first
study investigating the association of A54T polymorphism
in a Saudi population. The frequency of T allele of A54T
polymorphism was 0.29 similar to Greek and Caucasian
population [21-23]. A54T polymorphism was identified
via linkage disequilibrium map, as a haploblock spanning
50 kb that includes 22 SNPs. However, the T54 allele is
present in only one of six possibilities among the frequent
haplotypes (>2%). It is interesting that in this haploblock,
there are no other known or putative genes except for
FABP2 [24].
Previous studies of A54T polymorphisms investigated
lipid related diseases such as coronary artery disease (CAD)
[25]. Canani et al [26] showed that A54T polymorphism
confers susceptibility to renal disease in T2DM patients.
There are very few reports on the association of this poly-
morphism with T2DM. Several studies from non-European
ethnic backgrounds have reported a positive association
between FABP2 variants and T2DM. A54T polymorphism
was carried out in relation to multiple diseases and the re-
ports are summarize in Table 5, which shows positive as-
sociation with T2DM and a combination of other diseases
like chronic kidney disease, Microalbminuria, postprandial
fatty acids and with the glyburide therapy. In our study,
we have examined only T2DM (n = 438) samples and that
have not examined its association with other disease.
There are several studies denote no association of the
T allele with T2DM [27-29] and our study is supporting
the above mentioned studies. In some studies, subjects
were distributed in homozygous for the A allele (AA) and
T allele carriers (AT and TT), mainly because there were
only few subjects homozygous for the variant [23,30]. We
observed the association of A54T polymorphism withsm on different ethnic groups
Association Disease
No Obesity
Yes MI + chronic kidney disease
Yes Chronic kidney disease + T2DM
Yes Atherothrombic cerebral infarction
Yes T2DM + microalbminuria
No Lipid metabolism
Yes Renal disease + T2DM
Yes Postprandial fatty acids + T2DM
Yes Hypercholesterolemic
No T2DM
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tive, dominant and recessive). No association of A54T
polymorphism was found with T2DM according to any
genetic model used, a finding shared by other studies that
examined such an association [31]. There are limitations
to the study design as it is a case–control observational
study rather than cross sectional or prospective study. We
have chosen only one SNP (A54T) to study the T2DM
disease.
In conclusion, the present study provides no evidence of
any association between A54T polymorphism (rs1799883)
in FABP2 gene and T2DM, suggesting that A54T poly-
morphism is not a major risk factor for the T2DM. Over-
all, this study indicates that A54T polymorphism could
not affect directly the presence of T2DM due to the differ-
ential absorption of long chain fatty acids in the presence
of the T allele. This is the first study finding the interaction
between FABP2 and T2DM in Saudi population. Further
functional studies as well as well-characterized larger mo-
lecular epidemiological studies are necessary to confirm
our findings.
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